



Corporate Governance Policy – Securities Trading – Directors

Healthzone Limited
ACN 118 715 772

Dated: December 2010

Healthzone Limited
ACN 118 715 772
(Company)

Corporate Governance Policy – Securities Trading – Directors

- 1.1 This Policy imposes constraints on directors of the Company dealing in securities of the Company. It also imposes disclosure requirements on directors. The overriding policy is that there should be no dealings in the Company's shares, whether in permitted periods or at any other time, when a person is in possession of price sensitive information, or where the dealing is for short term or speculative gain.
- 1.2 This Policy was updated by the Board on 30 November 2010.
- 1.3 The Board recognises that it is the individual responsibility of each Director and other officers to oversee that they comply with the spirit and the letter of the insider trading laws, and that notification to the Board in no way implies Board approval of any transaction.

2. Application

- 2.1 This Policy applies only to directors of the Company. Senior executives who are not directors and other staff of the Company and its subsidiaries (**Group**) will be subject to separate policies in relation to trading in securities.

3. Objectives

- 3.1 The objectives of this Policy are to:
 - (1) minimise the risk of directors of the Company contravening the laws against insider trading;
 - (2) oversee that the Company is able to meet its reporting obligations under the ASX Listing Rules; and
 - (3) increase transparency with respect to trading in securities of the Company by directors.
- 3.2 To achieve these objectives directors should consider this Policy to be binding on them in the absence of specific exemption by the Board.

4. Dealing in securities – legal and other considerations

- 4.1 Sections 1042B to 1043O of the *Corporations Act 2001* prohibit persons who are in possession of price sensitive information in relation to particular securities that is not generally available to the public from:
- (1) dealing in the securities; or
 - (2) communicating the information to others who might deal in the securities.
- 4.2 The central test of what constitutes price sensitive information is found in section 1042A. It provides that the insider trading and continuous disclosure rules apply to information concerning a company that a reasonable person would expect to have a material effect on the price or value of securities in the company (**price sensitive information**).
- 4.3 Directors of the Company will from time to time be in a situation where they are in possession of price sensitive information that is not generally available to the public. Examples are the period prior to release of annual or half-yearly results to Australian Securities Exchange (**ASX**) and the period during which a major transaction is being negotiated.
- 4.4 The risk of contravention of insider trading laws in relation to information concerning public companies was substantially reduced in 1994 with the introduction of the continuous disclosure regime. Under that regime, public companies are required to disclose all price sensitive information immediately to ASX, except in limited circumstances. The tests of what constitute price sensitive information under the insider trading laws and under the continuous disclosure requirements are effectively identical. As a consequence, at least in theory, there is no risk of directors contravening insider trading laws as all relevant information will already have been disclosed.
- 4.5 There are a number of limitations and qualifications to the above. They include:
- (1) the ASX Listing Rules and the *Corporations Act* permit companies to not disclose certain information, for example in the situation where an acquisition is being negotiated and remains confidential;
 - (2) information may be known to a particular director but not yet by the Company as a whole (ie the Board);
 - (3) the Company may not have yet complied with its continuous disclosure obligations in relation to a particular event or circumstance – there will always be some element of delay in doing so; and
 - (4) directors will generally have a better feel for the performance of the Company than the public.

In these situations there is still potential for contravention. There is also the potential for an appearance of contravention even if there has not been actual contravention. This could reflect badly on the Company as well as on the director concerned.

4.6 Another circumstance that must be guarded against is where one or more directors are aware of an event or circumstance and the remaining directors are not yet aware. In such a circumstance it is important that no director deals in securities because:

- (1) there is a risk that they will be found to have been guilty of insider trading even if they had no intention of committing a contravention; and
- (2) of the potential for such circumstances to reflect badly on the Company.

4.7 For these reasons, the advice of the Chairman should be sought prior to any dealings taking place, and steps should be taken to monitor that the Chairman is apprised of all relevant considerations by the Continuous Disclosure Manager appointed under ASX Listing Rule 1.1, condition 12.

5. Policy – dealing in securities

5.1 Directors should not deal in securities of the Company unless:

- (1) they have satisfied themselves that they are not in possession of any price sensitive information that is not generally available to the public;
- (2) they have advised the Chairman of their intention to do so;
- (3) the Chairman has made appropriate enquiries of other directors; and
- (4) the Chairman has indicated that there is no impediment to them doing so.

5.2 The Chairman will generally allow directors to deal in securities of the Company as a matter of course (unless there is in existence price sensitive information that has not been disclosed because of an ASX Listing Rule exception) other than in the following periods:

- (1) within the period of 1 month prior to the release of annual or half-yearly results; and
- (2) within the period of 2 weeks prior to the annual general meeting.

Directors should wait at least 2 hours after the relevant release so that the market has had time to absorb the information before any dealing in securities.

- 5.3 Written clearance to trade in the Company's securities during the periods referred to in 5.2 above must be obtained from the Chairman.
- 5.4 Directors must not at any time engage in short-term trading in securities of the Company.
- 5.5 Directors must not communicate price sensitive information to a person who may deal in securities of the Company. In addition, a director should not recommend or otherwise suggest to any person (including a spouse, relative, friend, trustee of a family trust or directors of a family company) the buying or selling of securities in the Company.
- 5.6 Directors must monitor that external advisers who may receive price sensitive information are bound by confidentiality agreements or other enforceable confidentiality obligations.
- 5.7 The above principles also apply to the following:
 - (1) trading in financial products issued or created over the Company's securities and associated products; and
 - (2) entering into transactions with securities (or any derivative thereof) in associated products which operate to limit the economic risk of any unvested entitlements under any equity based remuneration schemes offered by the Company.
- 5.8 The Chairman must always seek approval from an Executive Director prior to dealing in any securities of the Company.

6. Notification of dealings in securities – legal and other considerations

- 6.1 ASX Listing Rules 3.19A and 3.19B require the Company to notify dealing in securities by directors within 5 business days. Three appendixes are included in the Listing Rules for the purpose of this notification, being 3X Initial Director's Interest Notice, 3Y Change of Director's Interest Notice and 3Z Final Director's Interest Notice.
- 6.2 Section 205G of the *Corporations Act 2001* requires a director of a listed company to notify ASX within 14 days of acquiring or disposing of a relevant interest in any securities of the Company. This is an obligation of the director, not the Company. There is no prescribed form for such notifications. ASIC have granted relief from the requirements of section 205G where notifications are made by the Company under Listing Rules 3.19A and 3.19B.

7. Policy – notification of dealing in securities

- 7.1 If any dealings in securities in the Company are proposed, there must be prior consultation with the Chairman in the case of directors and an Executive Directors in the case of the Chairman.
- 7.2 Directors must notify the Company Secretary immediately on acquiring or disposing of a relevant interest in any securities in the Company.
- 7.3 Directors are required to enter into an agreement with the Company under which they are obliged to notify changes in interests in shares and other relevant matters.

8. Explanation of terms

- 8.1 For the purposes of this Policy:
 - (1) **deal in securities** means buy or sell shares, options or other securities in the Company, or enter into transactions in relation to shares, options or other securities in the Company. It includes procuring another person to do any of these things; and
 - (2) **price sensitive information** has the meaning given in paragraph 4.1.
- 8.2 For the purposes of paragraph 5.1, directors' "dealing" includes associates of directors dealing in securities, and it is incumbent on each director to oversee that an associate does not deal in circumstances where the dealing could be attributed to the director concerned.



Corporate Governance Policy – Securities Trading – Executives

Healthzone Limited
ACN 118 715 772

Date: December 2010

Healthzone Limited
ACN 118 715 772
(Company)

Corporate Governance Policy – Securities Trading – Executives

1. Introduction

- 1.1 This policy imposes constraints on senior executives of the Company dealing in securities of the Company.
- 1.2 The policy was updated by the Board on 30 November 2010. Schedule 1 lists the titles of the senior executives who are subject to this policy on the date that it is issued. Other executives of equivalent seniority are also subject to this policy. If any executive is in doubt as to whether he or she is subject to this policy, he or she should consult the Chairman.

2. Application

- 2.1 The policy applies only to senior executives of the Company. Directors are subject to a separate policy in relation to trading in securities.

3. Dealing in Securities

- 3.1 Senior executives must not deal in securities of the Company unless:
 - (1) they have satisfied themselves that they are not in possession of any price sensitive information that is not generally available to the public;
 - (2) they have advised the Chairman of their intention to do so;
 - (3) the Chairman has indicated that there is no impediment to them doing so.
- 3.2 The Chairman will generally allow senior executives to deal in securities of the Company as a matter of course (unless there is in existence price sensitive information that has not been disclosed because of an ASX Listing Rule exception) other than in the following periods:

(1) within the period of 1 month prior to the announcement of interim and final results of the Company; and

(2) within the period of 2 weeks prior to the annual general meeting;

but only after waiting at least two hours after the relevant release so that the market has had time to absorb the information.

3.3 Written permission to trade in the Company's securities during the periods referred to in 3.2 above must be obtained from the Chairman.

3.4 A senior executive must not at any time engage in short-term trading in securities of the Company.

3.5 A senior executive must not communicate price sensitive information to a person who may deal in securities of the Company.

3.6 In addition, a senior executive must not recommend or otherwise suggest to any person (including a spouse, relative, friend, trustee of a family trust or directors of a family company) the buying or selling of securities in the Company.

3.7 The above principles also apply to the following:

(1) trading in financial products issued or created over the Company's securities and associated products; and

(2) entering into transactions with securities (or any derivative thereof) in associated products which operate to limit the economic risk of any unvested entitlements under any equity based remuneration schemes offered by the Company.

4. Notification

4.1 Senior executives must notify the Company Secretary immediately on acquiring or disposing of a relevant interest in any securities in the Company.

4.2 Senior executives must monitor that external advisers who may receive price sensitive information are bound by confidentiality agreements or other enforceable confidentiality obligations.

5. Consultation

5.1 If a senior executive has any query about the application of this policy, he or she should consult the Chairman.

6. Penalties

- 6.1 A trade in any securities by a person who is in possession of price sensitive information not publicly available could contravene the *Corporations Act 2001* and expose the person to civil and criminal penalties.
- 6.2 A contravention of this policy by an executive may result in summary dismissal.

Schedule 1
Executives to whom this Policy applies

Chief Financial Officer -	Finance;
Company Secretary -	Finance;
Financial Controller -	Finance;
General Manager –	Group Retail Services;
General Manager –	Sales & Operations; and
Company Accountants -	Finance.